Intra- and Interindividual Variability in the Free Fraction of Cyclosporine in Plasma in Recipients of Renal Transplants
- 1 November 1989
- journal article
- research article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 11 (6) , 623-630
- https://doi.org/10.1097/00007691-198911000-00002
Abstract
The protein binding of cyclosporine (CyA) in plasma was studied in serial samples for 6 months after transplantation in 66 renal transplant recipients. Analysis was performed with a recently developed method of equilibrium dialysis in steel chambers. Among the 1,848 samples, the free fraction ranged from 0.5 to 4.2%, with a median of 1.30%. The free fraction of CyA was highest immediately after transplantation (1.66 \Pm 0.49%). Diabetics had a higher free fraction of CyA than nondiabetics during the first 2 weeks after transplantation. A weak, but significant, covariation was observed between the serum concentration of albumin or bilirubin and the free fraction of CyA (r = −0.47 and r = 0.39, respectively; p < 0.01). There was also a significant correlation between serum HDL cholesterol (r = −0.39 to −0.48; p < 0.01), as well as apolipoprotein Al (r = −0.35 to −0.49; p < 0.01), and the free fraction of CyA. A significant drop in the free fraction of CyA was observed immediately prior to acute rejection episodes as compared with I week earlier (p < 0.01), but there was no difference in the free fraction of CyA between patients who lost their graft and those who did not. There was an overall eightfold variation in the free fraction of CyA in plasma, with an up to fivefold intraindividual variation and a 2.3-fold variation in the mean free fraction between individuals. A significant covariation was observed between the free fraction of CyA and the concentration of binding proteins in plasma, as well as factors such as time after transplantation, diagnosis, and clinical events. Thus, it is now possible to monitor free CyA, and this may prove useful in special situations, for example, in patients with dyslipoproteinemias.Keywords
This publication has 16 references indexed in Scilit:
- Interaction of cyclosporin A with human lipoproteinsJournal of Pharmacy and Pharmacology, 1986
- Restrictive Transport of a Lipid‐Soluble Peptide (Cyclosporin) Through the Blood–Brain BarrierJournal of Neurochemistry, 1985
- CYCLOSPORINE PLASMA LEVELS IN RENAL TRANSPLANT PATIENTSTransplantation, 1985
- Semi-automated high-performance liquid chromatographic determination of cyclosporine A in whole blood using one-step sample purification and column-switchingJournal of Chromatography B: Biomedical Sciences and Applications, 1985
- Influence of volume shifts on drug binding during equilibrium dialysis: Correction and attenuationJournal of Pharmacokinetics and Biopharmaceutics, 1983
- Immunonephelometric determination of apolipoprotein A-1 in hyperlipoproteinemic serum.Clinical Chemistry, 1983
- IMMUNOLOGICAL AND PHARMACOLOGICAL MONITORING IN THE CLINICAL USE OF CYCLOSPORIN AThe Lancet, 1981
- Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2European Journal of Immunology, 1981
- EFFECTS OF NEW ANTI-LYMPHOCYTIC PEPTIDE CYCLOSPORIN-A IN ANIMALS1977
- Serum Lipid and Lipoprotein Concentrations in Chronic UremiaActa Medica Scandinavica, 1976